Background The prognosis of high‐risk neuroblastoma patients has improved over the last
decades. However, many patients experience relapse after successful initial treatment. We …

Background Few randomized trials have been conducted in children with relapsed/refractory
neuroblastoma and data about outcomes including progression‐free survival (PFS) in these …

BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used
an objective “response” of measureable disease (Response Evaluation Criteria In Solid …

Abstract Background and Procedure Most deaths from neuroblastoma occur within 2 years
of diagnosis but there have been several anecdotal reports of relapse and death after much …

Background The survival rate among patients with intermediate-risk neuroblastoma who
receive dose-intensive chemotherapy is excellent, but the survival rate among patients who …

Background A comprehensive clinical long-term survey over the complete spectrum of
neuroblatoma disease is lacking in the literature. Objective Our objective was to describe the …

Background This study was done to investigate the long-term event free and overall survival
of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) …

Background Therapy for high‐risk neuroblastoma is intensive and multimodal, and
significant long‐term adverse effects have been described. The aim of this study was to …

Background Outcomes for high‐risk neuroblastoma remain poor. Modern treatment
protocols utilizing intense induction followed by myeloablative consolidation chemotherapy …

The Italian Neuroblastoma Registry was investigated to describe 781 children with
neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten …